AHNAK and Inflammatory Markers Predict Poor Survival in Laryngeal Carcinoma

AHNAK/Desmoyokin is a giant protein which has been recently linked to reorganization of the actin cytoskeleton, cellular migration and invasion. Here, we investigated the role of AHNAK in the pathophysiology of larynx carcinoma-one of the major subtypes of head and neck cancer. To this end, we analysed AHNAK expression in tumor tissues from 83 larynx carcinoma patients in relation to overall survival. We found that tumoral AHNAK overexpression significantly associated with poor survival of these patients both in univariate and multivariate analysis. In further studies, we combined the prognostic value of AHNAK with selected markers of inflammation, such as macrophage migration inhibitory factor (MIF) and tumor-infiltrating neutrophils (CD66b-positive cells). Both MIF and neutrophils have been linked to enhanced tumoral migration and poor clinical outcome in patients with orohypopharynx carcinoma-another major subtype of head and neck cancer. Interestingly, we found that synchronous high levels of AHNAK and MIF or AHNAK and neutrophils, respectively, were stronger predictors of poor survival than AHNAK alone. Synchronous high levels of all three markers were the strongest predictors of poor survival in our patient cohort. Taken together, our findings propose novel strategies for an accurate prognosis in larynx carcinoma and suggest potential mechanisms of inflammation-mediated tumor progression.

[1]  S. Lang,et al.  Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology , 2012, Cancer Immunology, Immunotherapy.

[2]  J. Bishop,et al.  The human gene AHNAK encodes a large phosphoprotein located primarily in the nucleus , 1993, The Journal of cell biology.

[3]  T. Whiteside,et al.  Tumor‐derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation , 2011, International journal of cancer.

[4]  Leonard J Foster,et al.  Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. , 2010, Cancer research.

[5]  Alyssa D Gregory,et al.  Tumor-associated neutrophils: new targets for cancer therapy. , 2011, Cancer research.

[6]  H. Shimizu,et al.  Desmoyokin/AHNAK protein localizes to the non-desmosomal keratinocyte cell surface of human epidermis. , 1995, The Journal of investigative dermatology.

[7]  T. Nishikawa,et al.  Regulation of translocation of the desmoyokin/AHNAK protein to the plasma membrane in keratinocytes by protein kinase C. , 1995, Experimental cell research.

[8]  E. Vokes,et al.  Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer , 2008, CA: a cancer journal for clinicians.

[9]  Xiao‐Yu Yin,et al.  Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. , 2011, Journal of hepatology.

[10]  C. Delphin,et al.  The Giant Protein AHNAK Is a Specific Target for the Calcium- and Zinc-binding S100B Protein , 2001, The Journal of Biological Chemistry.

[11]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[12]  R. Christopherson,et al.  iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL. , 2012, Journal of proteome research.

[13]  G. Jin,et al.  Identification of candidate cooperative genes of the Apc mutation in transformation of the colon epithelial cell by retroviral insertional mutagenesis , 2008, Cancer science.

[14]  R. Kraft,et al.  Signaling from β‐adrenoceptor to L‐type calcium channel: identification of a novel cardiac protein kinase A target possessing similarities to AHNAK , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  R. Bucala,et al.  Macrophage migration inhibitory factor: a probable link between inflammation and cancer. , 2007, Immunity.

[16]  J. Meldolesi,et al.  Regulated exocytosis: a novel, widely expressed system , 2002, Nature Cell Biology.

[17]  André Scherag,et al.  Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease , 2011, International journal of cancer.

[18]  F. Cohen,et al.  A human gene (AHNAK) encoding an unusually large protein with a 1.2-microns polyionic rod structure. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Lang,et al.  A novel p38‐MAPK signaling axis modulates neutrophil biology in head and neck cancer , 2012, Journal of leukocyte biology.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[21]  B. Mack,et al.  Allogenic antibody-mediated identification of head and neck cancer antigens. , 2004, Biochemical and biophysical research communications.

[22]  S. Lang,et al.  Protumor and antitumor functions of neutrophil granulocytes , 2012, Seminars in Immunopathology.

[23]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[24]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[25]  J. Quigley,et al.  Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. , 2011, The American journal of pathology.

[26]  S. Weiss,et al.  Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. , 2010, The Journal of clinical investigation.

[27]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[28]  D. Stokoe,et al.  Protein kinase B phosphorylates AHNAK and regulates its subcellular localization , 2001, The Journal of cell biology.

[29]  J. Bernhagen,et al.  Macrophage migration inhibitory factor (MIF): a promising biomarker. , 2010, Drug news & perspectives.

[30]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.